Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

INTRODUCTION: Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance therapy in patients in remission should be considered in order...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Buhl, Sine Schnoor, Steenholdt, Casper, Brynskov, Jørn, Thomsen, Ole Østergaard, Bendtzen, Klaus, Ainsworth, Mark Andrew
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2014
Matèries:
Gastroenterology and Hepatology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4275671/
https://ncbi.nlm.nih.gov/pubmed/25524543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005887
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars